In response to community demand, OmniLife has launched an open $250,000 CF round of investment through Wunderfund.co to enable the passionate organ donation community to participate in providing innovative solutions to the industry. Open to non-institutional, private investors with lower investment minimums and no accreditation requirements, the funds raised with this crowd-sourced opportunity will be used to support the commercialization of the company’s newest product, a communication-centric workflow tool allowing providers to collaborate on cases together to increase efficiency, transparency and coordination in order to place more organs and tissues and save more lives.
Over the last four years, OmniLife has developed the largest collaboration and communication network specifically for transplant and donation professionals, with new organizations and partners joining every day. Working with their advisors and investors, OmniLife has now created an innovative way for supporters of any size to participate in the company’s mission in a more meaningful way.
“This is a great opportunity for our passionate followers to get involved with an innovative startup that is changing the allotransplantation (organ, tissue, cell) industry,” Dalton Shaull, CEO of OmniLife, said. “As a certified Benefit Corporation, we have a focus and commitment to social betterment, and it’s really exciting and rewarding to be able to offer a solution that allows these folks to be a part of our movement in the industry.”
To find out more details, please visit www.wunderfund.co/omnilife.
OmniLife is a nationally recognized communication technology platform dedicated to the unique needs of transplant and donation professionals. Over the past four years, the company has built the nation’s largest communication and collaboration network dedicated completely to the unique needs of transplant and donation professionals.
OmniLife’s founders were recognized in the 2018 HealthCare edition of Forbes 30 Under 30. The company was recently awarded $2M in Phase I & II grants by the National Institutes of Health (NIH) Small Business Innovation Research (SBIR), with the resulting Phase I study showing promising results which have been accepted for publication in the industry journal “Progress in Transplantation.” OmniLife’s technology has been incorporated into donation and transplant specialties nationally and has facilitated over 1,000 life-saving transplants to date.